Abstract 1930P
Background
Iodine refractory differentiated thyroid cancer (DTC) carries a poor prognosis. BRAF/MEK/MAPK pathway activation is associated with loss of expression of iodine-metabolizing genes in thyroid cancer, resulting in iodine refractoriness. BRAF, MEK inhibitors have previously been shown to resensitize iodine refractory DTC in small clinical trials, however, the optimal drug/drug combination and duration of resensitization remain to be elucidated.
Methods
This is a single-center, retrospective study of resensitization of BRAF-mutated iodine-refractory DTC using both dabrafenib and trametinib (DT) between January 2020 and April 2024. Successful resensitization was defined as significant uptake of 131I on the posttreatment whole body scan (WBS); median duration of response was calculated from initiation of RAI treatment. Duration of resensitization, thyroglobulin levels were also collected.
Results
A total of 19 patients were included in the final analysis, with median age of 66 years, 53% (10/19) females, and 58% (11/19) Caucasian, 32% (6/19) Hispanic and 10% (2/19) Native American. All patients were confirmed to have BRAF V600E mutation; 84% (16/19) had distant metastasis; 84% (16/19) had baseline WBS without iodine uptake; 16% (3/19) had progression of disease 3 months after the previous RAI ablation. Median duration of resensitization was 6 months (range 3-16); 90% (17/19) of patients achieved successful resensitization. Of note, 4 patients did not resensitize at 6 to 12 weeks but after 6 months. Interestingly, for patients without baseline thyroglobulin antibody, marked elevation of thyroglobulin level correlated very well with successful resensitization in 80% (12/15) of patients. At median follow-up of 10 months (range 1-33), no patients with successful resensitization had progression of disease. Combination of DT were well tolerated, 5 patients experienced severe confusion, renal failure or hyponatremia, requiring dose reduction of dabrafenib, but were able to complete the treatment.
Conclusions
Longer duration of dabrafenib and trametinib appears to be safe and more effective on resensitization of BRAF-mutated iodine refractory DTC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J.J. Niu: Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, G1 Therapeutics, Mirati Therapeutics, Pfizer, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
1465P - Potential impact of APC mutation on survival via immune evasion through WNT signaling activation in HER2-positive gastric cancer treated with trastuzumab (tmab), nivolumab (nivo), and chemotherapy
Presenter: Takeru Wakatsuki
Session: Poster session 18
1468P - cGAS-driven inflammation in chromosomally unstable oesophagogastric adenocarcinoma
Presenter: Eileen Parkes
Session: Poster session 18
1469P - Development of an efficacy prediction model for concurrent chemoradiotherapy in esophageal squamous cell carcinoma using deep learning and multimodal data integration
Presenter: Xin Yang
Session: Poster session 18
1470TiP - Phase I trial of intraperitoneal infusion of GAIA-102 of NK-Like CD3-negative cells for gastric/pancreatic cancer
Presenter: Eiji Oki
Session: Poster session 18
1471TiP - MK-2870-015: A phase III study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) vs treatment of physician’s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)
Presenter: Zev Wainberg
Session: Poster session 18
1472TiP - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group – The IKF-057/ PRESTO trial
Presenter: Nils Homann
Session: Poster session 18
1473TiP - Neoadjuvant SOX combined with cadonilimab (AK104) for PD-L1 negative upper GC/GEJC patients
Presenter: Zhen Yuan
Session: Poster session 18
1474TiP - A randomized phase II study of disitamab vedotin (DV) plus toripalimab and chemotherapy versus DV plus toripalimab versus chemotherapy as perioperative treatment for HER2-expressing locally advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ)
Presenter: Ziyu Li
Session: Poster session 18